Scribe Therapeutics disclosed a second success milestone in its collaboration with Eli Lilly’s subsidiary Prevail Therapeutics, marking a key step toward clinical development of in‑vivo CRISPR therapies for neurological and neuromuscular diseases. The milestone was announced on February 17, 2026, following the partnership that began in May 2023 and is valued at more than $1.5 billion in potential milestone payments and royalties.
The milestone represents the second major achievement in the partnership, following a first milestone announced in April 2025. While the specific nature of the achievement was not detailed, it confirms that the preclinical program is progressing toward the next phase of development. The collaboration leverages Scribe’s X‑Editor (XE) technology and CRISPR by Design platform to enhance safety, specificity, and delivery of gene‑editing therapies.
"This milestone reflects strong execution and continued validation of our in‑vivo CRISPR technologies by a partner with deep technical and clinical rigor," said Benjamin Oakes, CEO of Scribe Therapeutics. The statement underscores the confidence that both companies have in the platform’s potential to address unmet needs in neurological and neuromuscular disorders.
The partnership, which began in May 2023, is part of Lilly’s broader strategy to diversify its pipeline beyond its flagship obesity and diabetes products. By advancing programs through collaborations, Lilly aims to expand its therapeutic portfolio and reduce reliance on its core drug categories. The milestone’s progress signals that the joint effort is on track to move the program into clinical trials, potentially opening new revenue streams for both companies.
The collaboration’s potential value exceeds $1.5 billion in milestone payments and royalties, indicating significant upside if the program reaches the clinic.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.